Jan Willem Cohen Tervaert MD, PhD

Presentation: The management of Breast implant illness: who will benefit from explantation and what to do thereafter?

​

Biography:

Jan Willem Cohen Tervaert MD, PhD

Cohen Tervaert studied Medicine at the University of Groningen, the Netherlands, where he obtained his MD in 1981. After training in Internal Medicine and Nephrology, he finished his thesis cum laude in 1990 entitled "ANCA: new class of autoantibodies in glomerulonephritis and vasculitis".

Subsequently, he worked as a visiting researcher in the Vascular Biology Department, Harvard Medical School Boston, USA (Head: Prof. MA Gimbrone Jr.).

In 1993, he returned to Groningen (as a recipient of a fellowship of the Royal Netherlands Academy of Arts and Sciences), where he was a staff member at the Division of Clinical Immunology, Department of Medicine, at the University Medical Center Groningen.

In 2000, he was appointed Professor of Medicine and Immunology at the Maastricht University, Maastricht, the Netherlands.

From 2002 -2006, he was a member of the WHO committee assessing autoimmunity associated with exposure to chemicals.

In 2020, he was appointed as a member of the European Commission expert panel on medical devices.

 

Furthermore, he was until 2012 chairman of the Division of Clinical and Experimental Immunology of the Department of Internal Medicine and head of the Immunology Laboratory at the Maastricht University Medical Center.

From 2012 -2015, he was Research Director of the Sint Franciscus Vlietland Group in Rotterdam, the Netherlands (one of the largest “top-clinical hospitals” of the country).

Currently, he is a Professor at the University of Alberta, Edmonton, Canada, where he is since November 1st, 2017 the Director of the Division of Rheumatology.

Cohen Tervaert is a founding member of the Autoimmunity Consortium, of the North American Vascular Biology Organization and of the Dutch Vasculitis Study Group.

He is a former Chairman of the scientific advisory board of the Dutch Arthritis Foundation (“Reumafonds”), a former chairman of the Dutch Scientific Section of Nephrology and a former board member of the Dutch Federation of Nephrology and the Dutch Society of Immunology.

He was (until recently) a member of the scientific advisory board of The National Health Care Institute that advises the Dutch Minister of Health, Welfare, and Sports on health care coverage and medications in the Netherlands, a member of the Netherlands National Institute for Public Health and the Environment committee on Chromium-VI and a member of the Health Council of the Netherlands committee on ME/CFS.

His fields of interest are inflammation and autoimmunity of vascular disorders, such as atherosclerosis and vasculitis. Genes and the interplay with environmental factors such as vitamin D, S. aureus, silica, and foreign body implantation such as silicones and polypropylene mesh in the development of autoimmunity have his special interest. Recently, he started together with Dr. Mo Osman a laboratory in which the role of mitochondrial dysfunction in relation to fatigue and NK cells is investigated in diseases such as vasculitis, systemic sclerosis, ASIA, fibromyalgia and COVID-19.

He is (co) author of more than 440 scientific articles that are cited in over > 29.600 publications. He is a member of Editorial Boards of 3 scientific journals. His Hirsch factor per 01-07-2020 is 87.

 

KEY PUBLICATIONS

1. Cohen Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, Meijer S, van der Giessen M, The TH, van der Hem GK, Kallenberg CGM. Association between active Wegener's Granulomatosis and anticytoplasmic antibodies. Arch Int Med, 1989;149:2461-2465.

 2. Cohen Tervaert JW, Huitema MG, Hene RJ, et al. Prevention of relapses of Wegener’s Granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336:709-711.

 3. Stegeman CA, Cohen Tervaert JW, De Jong PE, et al. Trimethoprimsulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. N Engl J Med 1996; 335:16-20.

4. Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.

5. Jones RB, Cohen Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA associated renal vasculitis. New Engl J Med 2010;363:211-220

 6. Wilde B, Van Paassen P, Witzke O, Cohen Tervaert JW. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011;79:599-612

7. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012 Jul 19;367(3):214-23.

8. Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Revised 2017 International Consensus on testing of ANCA in small vessel vasculitis. Nature Rev Rheumatol 2017 Nov;13(11):683-692.

.

9. Moiseev S, Bossuyt X, Arimura Y, Blockmans D, Csernok E, Damoiseaux J, Emmi G, Flores-Suárez LF, Hellmich B, Jayne D, Jennette JC, Little MA, Mohammad AJ, Moosig F, Novikov P, Pagnoux C, Radice A, Sada KE, Segelmark M, Shoenfeld Y, Sinico RA, Specks U, Terrier B, Tzioufas AG, Vaglio A, Zhao MH, Cohen Tervaert JW; European EGPA Study Group. International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. Am J Respir Crit Care Med. 2020 Jun 25. doi: 10.1164/rccm.202005-1628SO. 

 

10. Osman MS, van Eeden C, Cohen Tervaert JW. Fatal COVID-19 infections: Is NK cell dysfunction a link with autoimmune HLH? Autoimmun Rev. 2020 Jul;19(7):102561. doi: 10.1016/j.autrev.2020.102561

10.1016/j.autrev.2020.102561